Financhill
Sell
41

MESO Quote, Financials, Valuation and Earnings

Last price:
$17.22
Seasonality move :
4.35%
Day range:
$16.80 - $17.52
52-week range:
$9.61 - $22.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
118.82x
P/B ratio:
4.32x
Volume:
138.6K
Avg. volume:
177.7K
1-year change:
41.67%
Market cap:
$2.2B
Revenue:
$17.2M
EPS (TTM):
-$0.85

Analysts' Opinion

  • Consensus Rating
    Mesoblast Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $35.00, Mesoblast Ltd. has an estimated upside of 106.73% from its current price of $16.93.
  • Price Target Downside
    According to analysts, the lowest downside price target is $35.00 representing 100% downside risk from its current price of $16.93.

Fair Value

  • According to the consensus of 1 analyst, Mesoblast Ltd. has 106.73% upside to fair value with a price target of $35.00 per share.

MESO vs. S&P 500

  • Over the past 5 trading days, Mesoblast Ltd. has overperformed the S&P 500 by 5.41% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Mesoblast Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Mesoblast Ltd. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Mesoblast Ltd. reported revenues of --.

Earnings Growth

  • Mesoblast Ltd. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Mesoblast Ltd. reported earnings per share of --.
Enterprise value:
2.2B
EV / Invested capital:
--
Price / LTM sales:
118.82x
EV / EBIT:
--
EV / Revenue:
128.54x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-38.58x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$5.7M
Return On Assets:
--
Net Income Margin (TTM):
-593.86%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2021-06-30 2022-06-30 2023-06-30 2022-06-30 2023-06-30
Income Statement
Revenue $7.5M $10.2M $7.7M $2.2M $2.1M
Gross Profit -- -- -- -$8.8M -$6.5M
Operating Income -$107.5M -$80.8M -$68.8M -$19.8M -$18.7M
EBITDA -$87.7M -$73M -$58.5M -- -$17.3M
Diluted EPS -$1.55 -$63.40 -$51.23 -$0.31 -$0.27
Period Ending 2021-06-30 2022-06-30 2023-06-30 2024-06-30 2025-06-30
Balance Sheet
Current Assets $148.2M $69.8M $81.7M $86.5M --
Total Assets $824.9M $750.4M $669.4M $669.2M --
Current Liabilities $94.3M $51.4M $42M $73.2M --
Total Liabilities $243.5M $253.3M $167.6M $188.8M --
Total Equity $581.4M $497M $501.8M $480.4M --
Total Debt $94.2M $96.6M $108.8M -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-06-30 2024-06-30 2025-06-30 2024-06-30 2025-06-30
Cash Flow Statement
Cash Flow Operations -- -$55.5M -$56.6M -$48.5M --
Cash From Investing -- -$96.6K $120K -$28K -$440K
Cash From Financing -- $47.3M $154M -$3M -$4.8M
Free Cash Flow -$63.6M -$55.8M -$57.3M -- --
MESO
Sector
Market Cap
$2.2B
$28.4M
Price % of 52-Week High
76.96%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-11.75%
-1.32%
1-Year Price Total Return
41.67%
-22.19%
Beta (5-Year)
2.025
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $16.52
200-day SMA
Buy
Level $13.98
Bollinger Bands (100)
Buy
Level 0 - 0
Chaikin Money Flow
Sell
Level --
20-day SMA
Buy
Level $15.63
Relative Strength Index (RSI14)
Buy
Level 59.03
ADX Line
Neutral
Level 0
Williams %R
Neutral
Level -24.7839
50-day SMA
Buy
Level $16.57
MACD (12, 26)
Buy
Level 0.16
25-day Aroon Oscillator
Buy
Level 52
On Balance Volume
Neutral
Level --

Financial Scores

Hold
Altman Z-Score (Annual)
Level (2.576)
Buy
CA Score (Annual)
Level (0.2643)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (0.2247)
Buy
Piotroski F Score (Annual)
Level (6)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Stock Forecast FAQ

In the current month, MESO has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MESO average analyst price target in the past 3 months is $35.00.

  • Where Will Mesoblast Ltd. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Mesoblast Ltd. share price will rise to $35.00 per share over the next 12 months.

  • What Do Analysts Say About Mesoblast Ltd.?

    Analysts are divided on their view about Mesoblast Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mesoblast Ltd. is a Sell and believe this share price will drop from its current level to $35.00.

  • What Is Mesoblast Ltd.'s Price Target?

    The price target for Mesoblast Ltd. over the next 1-year time period is forecast to be $35.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is MESO A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Mesoblast Ltd. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.

  • How Can I Buy Shares Of MESO?

    You can purchase shares of Mesoblast Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mesoblast Ltd. shares.

  • What Is The Mesoblast Ltd. Share Price Today?

    Mesoblast Ltd. was last trading at $17.22 per share. This represents the most recent stock quote for Mesoblast Ltd.. Yesterday, Mesoblast Ltd. closed at $16.93 per share.

  • How To Buy Mesoblast Ltd. Stock Online?

    In order to purchase Mesoblast Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Google Vs NVIDIA Stock: Which Is Best?
Google Vs NVIDIA Stock: Which Is Best?

Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…

How High Could NVIDIA Stock Go?
How High Could NVIDIA Stock Go?

NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…

Stock Ideas

Buy
51
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 61x

Buy
61
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 38x

Buy
69
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Alerts

Sell
47
PSTG alert for Dec 4

Pure Storage, Inc. [PSTG] is up 5.05% over the past day.

Sell
41
SMX alert for Dec 4

SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.

Sell
43
HY alert for Dec 4

Hyster-Yale, Inc. [HY] is up 1.92% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock